Anzeige
Mehr »
Login
Mittwoch, 22.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Die Wachstumsgeschichte: Analysten sehen kurzfristige +37 %-Chance bei diesem europäischen Marktführer
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3C4ZC | ISIN: US98422E1038 | Ticker-Symbol: 2B30
Tradegate
21.05.24
15:21 Uhr
1,870 Euro
+0,014
+0,75 %
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
XERIS BIOPHARMA HOLDINGS INC Chart 1 Jahr
5-Tage-Chart
XERIS BIOPHARMA HOLDINGS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,8101,87021.05.
1,7781,93521.05.

Aktuelle News zur XERIS BIOPHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
09.05.Xeris Biopharma Holdings Inc reports results for the quarter ended in January - Earnings Summary1
09.05.Xeris Pharmaceuticals GAAP EPS of -$0.14 misses by $0.02, revenue of $40.64M misses by $1.17M1
09.05.Xeris Biopharma Holdings, Inc. - 8-K, Current Report1
09.05.Xeris Biopharma Reports First Quarter 2024 Financial Results and Recent Events57CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative...
► Artikel lesen
06.05.Xeris, Beta Bionics collab on glucagon product for pumps1
06.05.Why Are Xeris Biopharma Shares Moving Monday?1
06.05.Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement With Beta Bionics184For development and commercialization of a new and unique formulation of liquid stable glucagon for use in a bi-hormonal pump and pump systems.CONCORD, MA / ACCESSWIRE / May 6, 2024 / Xeris Biopharma...
► Artikel lesen
28.03.Xeris gains as Oppenheimer highlights drug technology5
15.03.Xeris Biopharma director buys $9,720 in company stock2
07.03.Earnings call: Xeris Biopharma reports robust growth and strategic refinancing4
06.03.Xeris Biopharma Holdings, Inc. - S-8, Securities to be offered to employees in employee benefit plans4
06.03.Xeris Biopharma Holdings, Inc. - 10-K, Annual Report3
06.03.Xeris Biopharma Holdings Inc reports results for the quarter ended in December - Earnings Summary5
06.03.Xeris Biopharma Holdings, Inc. - 8-K, Current Report2
06.03.Xeris Pharmaceuticals GAAP EPS of -$0.10 in-line, revenue of $44.39M beats by $0.84M3
06.03.Xeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Events149CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative...
► Artikel lesen
05.03.Earnings Outlook For Xeris Biopharma Holdings3
05.03.Xeris Pharmaceuticals Q4 2023 Earnings Preview2
11.01.Xeris (XERS) Up on Licensing Deal With Amgen to Develop Tepezza19
10.01.Why Is Xeris Biopharma (XERS) Stock Up 12% Today?5
Seite:  Weiter >>
30 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1